ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

NPS Pharma to Receive $25 Million from Amgen for Royalty Rights for Sensipar

By Victoria Stilwell NPS Pharmaceuticals Inc. (NPSP) will receive a one-time $25 million payment this month in exchange for its rights to receive royalties earned after 2018 for sales of its Sensipar drug under an amended license agreement with Amgen Inc. (AMGN). Sensipar, marketed as Mimpara in Europe, treats secondary hyperparathyroidism in chronic kidney disease patients on dialysis. In 1996 NPS licensed world-wide rights to Amgen to develop and commercialize the drug, and the drug received FDA approval in March 2004. NPS said funds from the agreement are expected to support the launches of both Gattex, a treatment for short bowel syndrome, and Natpara, which is intended to be used for adult hypoparathyroidism, in addition to aiding its transition into a self-sustaining commercial-stage business. The deal is expected to accelerate cash flow with at least $75 million of incremental cash expected through 2013. The amendment also extends the royalty-advance-repayment period, limiting the offset of the royalty advance that the biopharmaceutical company received from Amgen in August 2011 to $8 million a quarter. After repayment of the advance and a 9% anum discount factor on the balance of $92 million, Amgen will resume paying NPS all royalties earned through 2018. "This innovative transaction underscores our commitment to accessing capital at the lowest possible cost and in a manner that is in the best interests of our shareholders," said Luke M. Beshar, NPS's chief financial officer. Shares of NPS were inactive in premarket trade at $8.61, while shares of Amgen slipped 0.2% to $72.75. NPS is up 31% so far this year, while Amgen is up 14%. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/25/201406:03:01Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment...
07/02/201417:06:33Bind Therapeutics, Amgen End Collaboration on Targeted Cancer...
06/20/201421:35:07Atara Biotherapeutics, Backed by Carlos Slim, Files for IPO
06/09/201418:12:243M Finance Chief Departs for Amgen -- 2nd Update
06/09/201417:08:393M Finance Chief Departs for Amgen -- Update
05/12/201408:58:08U.S. Hot Stocks: Hot Stocks to Watch
05/12/201402:54:55AstraZeneca, Amgen Announce Positive Phase III Brodalumab Study
05/09/201418:31:12Amgen, AstraZeneca Announce Positive Results from Brodalumab...
04/22/201419:35:35Correction to Amgen Earnings Story
04/20/201406:17:33MARKET SNAPSHOT: Long View On Stocks Is Best During Weak Earnings...
04/11/201419:36:07Riding the Tech Roller Coaster
03/30/201408:44:49New Drugs to Lower Cholesterol Show Promise: Studies
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/17/201410:14:16Amgen Says Cholesterol Drug Study Meets Primary Endpoint
03/07/201417:42:46FDA Advises of Adverse Effects from New Cholesterol Drugs
02/05/201408:18:12Lazard Ltd. Swings to Fourth-Quarter Profit
02/05/201408:10:08Merck 4Q Profit Falls 14%; Confirms Collaborations
02/05/201407:47:05Merck Profit Falls 14% on Sales Drop; Confirms Collaborations...
01/28/201417:20:06Amgen Profit Rises 30% on Broad Sales Growth
01/26/201408:16:39MARKET SNAPSHOT: Stock Investors Trash Market Darlings, Face...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad